Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma

BACKGROUND: BCL2L13 belongs to the BCL2 super family, with its protein product exhibits capacity of apoptosis-mediating in diversified cell lines. Previous studies have shown that BCL2L13 has functional consequence in several tumor types, including ALL and GBM, however, its function in kidney cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Fei, Zhang, Luojin, Zhang, Mingjun, Ye, Kaiqin, Guo, Wei, Liu, Yu, Yang, Wulin, Zhai, Zhimin, Wang, Hongzhi, Xiao, Jun, Dai, Haiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247248/
https://www.ncbi.nlm.nih.gov/pubmed/34193180
http://dx.doi.org/10.1186/s12935-021-02039-y
_version_ 1783716481776746496
author Meng, Fei
Zhang, Luojin
Zhang, Mingjun
Ye, Kaiqin
Guo, Wei
Liu, Yu
Yang, Wulin
Zhai, Zhimin
Wang, Hongzhi
Xiao, Jun
Dai, Haiming
author_facet Meng, Fei
Zhang, Luojin
Zhang, Mingjun
Ye, Kaiqin
Guo, Wei
Liu, Yu
Yang, Wulin
Zhai, Zhimin
Wang, Hongzhi
Xiao, Jun
Dai, Haiming
author_sort Meng, Fei
collection PubMed
description BACKGROUND: BCL2L13 belongs to the BCL2 super family, with its protein product exhibits capacity of apoptosis-mediating in diversified cell lines. Previous studies have shown that BCL2L13 has functional consequence in several tumor types, including ALL and GBM, however, its function in kidney cancer remains as yet unclearly. METHODS: Multiple web-based portals were employed to analyze the effect of BCL2L13 in kidney cancer using the data from TCGA database. Functional enrichment analysis and hubs of BCL2L13 co-expressed genes in clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) were carried out on Cytoscape. Evaluation of BCL2L13 protein level was accomplished through immunohistochemistry on paraffin embedded renal cancer tissue sections. Western blotting and flow cytometry were implemented to further analyze the pro-apoptotic function of BCL2L13 in ccRCC cell line 786-0. RESULTS: BCL2L13 expression is significantly decreased in ccRCC and pRCC patients, however, mutations and copy number alterations are rarely observed. The poor prognosis of ccRCC that derived from down-regulated BCL2L13 is independent of patients’ gender or tumor grade. Furthermore, BCL2L13 only weakly correlates with the genes that mutated in kidney cancer or the genes that associated with inherited kidney cancer predisposing syndrome, while actively correlates with SLC25A4. As a downstream effector of BCL2L13 in its pro-apoptotic pathway, SLC25A4 is found as one of the hub genes that involved in the physiological function of BCL2L13 in kidney cancer tissues. CONCLUSIONS: Down-regulation of BCL2L13 renders poor prognosis in ccRCC and pRCC. This disadvantageous factor is independent of any well-known kidney cancer related genes, so BCL2L13 can be used as an effective indicator for prognostic evaluation of renal cell carcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02039-y.
format Online
Article
Text
id pubmed-8247248
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82472482021-07-06 Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma Meng, Fei Zhang, Luojin Zhang, Mingjun Ye, Kaiqin Guo, Wei Liu, Yu Yang, Wulin Zhai, Zhimin Wang, Hongzhi Xiao, Jun Dai, Haiming Cancer Cell Int Primary Research BACKGROUND: BCL2L13 belongs to the BCL2 super family, with its protein product exhibits capacity of apoptosis-mediating in diversified cell lines. Previous studies have shown that BCL2L13 has functional consequence in several tumor types, including ALL and GBM, however, its function in kidney cancer remains as yet unclearly. METHODS: Multiple web-based portals were employed to analyze the effect of BCL2L13 in kidney cancer using the data from TCGA database. Functional enrichment analysis and hubs of BCL2L13 co-expressed genes in clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) were carried out on Cytoscape. Evaluation of BCL2L13 protein level was accomplished through immunohistochemistry on paraffin embedded renal cancer tissue sections. Western blotting and flow cytometry were implemented to further analyze the pro-apoptotic function of BCL2L13 in ccRCC cell line 786-0. RESULTS: BCL2L13 expression is significantly decreased in ccRCC and pRCC patients, however, mutations and copy number alterations are rarely observed. The poor prognosis of ccRCC that derived from down-regulated BCL2L13 is independent of patients’ gender or tumor grade. Furthermore, BCL2L13 only weakly correlates with the genes that mutated in kidney cancer or the genes that associated with inherited kidney cancer predisposing syndrome, while actively correlates with SLC25A4. As a downstream effector of BCL2L13 in its pro-apoptotic pathway, SLC25A4 is found as one of the hub genes that involved in the physiological function of BCL2L13 in kidney cancer tissues. CONCLUSIONS: Down-regulation of BCL2L13 renders poor prognosis in ccRCC and pRCC. This disadvantageous factor is independent of any well-known kidney cancer related genes, so BCL2L13 can be used as an effective indicator for prognostic evaluation of renal cell carcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02039-y. BioMed Central 2021-06-30 /pmc/articles/PMC8247248/ /pubmed/34193180 http://dx.doi.org/10.1186/s12935-021-02039-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Primary Research
Meng, Fei
Zhang, Luojin
Zhang, Mingjun
Ye, Kaiqin
Guo, Wei
Liu, Yu
Yang, Wulin
Zhai, Zhimin
Wang, Hongzhi
Xiao, Jun
Dai, Haiming
Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma
title Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma
title_full Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma
title_fullStr Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma
title_full_unstemmed Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma
title_short Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma
title_sort down-regulation of bcl2l13 renders poor prognosis in clear cell and papillary renal cell carcinoma
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247248/
https://www.ncbi.nlm.nih.gov/pubmed/34193180
http://dx.doi.org/10.1186/s12935-021-02039-y
work_keys_str_mv AT mengfei downregulationofbcl2l13renderspoorprognosisinclearcellandpapillaryrenalcellcarcinoma
AT zhangluojin downregulationofbcl2l13renderspoorprognosisinclearcellandpapillaryrenalcellcarcinoma
AT zhangmingjun downregulationofbcl2l13renderspoorprognosisinclearcellandpapillaryrenalcellcarcinoma
AT yekaiqin downregulationofbcl2l13renderspoorprognosisinclearcellandpapillaryrenalcellcarcinoma
AT guowei downregulationofbcl2l13renderspoorprognosisinclearcellandpapillaryrenalcellcarcinoma
AT liuyu downregulationofbcl2l13renderspoorprognosisinclearcellandpapillaryrenalcellcarcinoma
AT yangwulin downregulationofbcl2l13renderspoorprognosisinclearcellandpapillaryrenalcellcarcinoma
AT zhaizhimin downregulationofbcl2l13renderspoorprognosisinclearcellandpapillaryrenalcellcarcinoma
AT wanghongzhi downregulationofbcl2l13renderspoorprognosisinclearcellandpapillaryrenalcellcarcinoma
AT xiaojun downregulationofbcl2l13renderspoorprognosisinclearcellandpapillaryrenalcellcarcinoma
AT daihaiming downregulationofbcl2l13renderspoorprognosisinclearcellandpapillaryrenalcellcarcinoma

Ejemplares similares